A nutritional composition having a total energy content of 67 kcal/100 ml or lower and including: a protein content which is 1.25 g/100 ml or lower, an energy content from protein of 7.2-8.4% of the total energy content of the nutritional composition, an energy content from fat which is at least 49% or more of the total energy content of the nutritional composition, a medium chain fatty acid content comprising 8 to 10 carbons which is less than 3 wt % of total amount of fatty acids, a sialic acid content of 10-25 mg/100 ml, a cholesterol content of 5-10 mg/100 ml, and a sphingomyelin content of 9-15 mg/100 ml is disclosed.

A nutritional composition having a total energy content of 67 kcal/100 ml or lower and including: a protein content which is 1.25 g/100 ml or lower, an energy content from protein of 7.2-8.4% of the total energy content of the nutritional composition, an energy content from fat which is at least 49% or more of the total energy content of the nutritional composition, a medium chain fatty acid content comprising 8 to 10 carbons which is less than 3 wt % of total amount of fatty acids, a sialic acid content of 10-25 mg/100 ml, a cholesterol content of 5-10 mg/100 ml, and a sphingomyelin content of 9-15 mg/100 ml is disclosed.

Disclosed is a method for producing agglomerated proteins, agglomerated protein powders, and instantized protein powders using at least one protein binder to form agglomerates of at least one target protein.

Disclosed is a method for producing agglomerated proteins, agglomerated protein powders, and instantized protein powders using at least one protein binder to form agglomerates of at least one target protein.

Infant formulas that include at least one human milk oligosaccharide selected from 2′-fucosyllactose (2′-FL) and lacto-N-neotetraose (LNnT), polyunsaturated fatty acids (PUFAs) docosahexaenoic acid (DHA) and arachidonic acid (AA), where the AA and DHA are present in an n-6/n-3 ratio of between 1 and 1.8, at least 30 mg/L of nucleotides, where the nucleotides include inosine monophosphate, and at least 30 μg/L of lutein are disclosed. Also provided are methods of use of the infant formulas for improving at least one of cognition, learning, and memory in an infant. The methods include administering the infant formulas to an infant.

Infant formulas that include at least one human milk oligosaccharide selected from 2′-fucosyllactose (2′-FL) and lacto-N-neotetraose (LNnT), polyunsaturated fatty acids (PUFAs) docosahexaenoic acid (DHA) and arachidonic acid (AA), where the AA and DHA are present in an n-6/n-3 ratio of between 1 and 1.8, at least 30 mg/L of nucleotides, where the nucleotides include inosine monophosphate, and at least 30 μg/L of lutein are disclosed. Also provided are methods of use of the infant formulas for improving at least one of cognition, learning, and memory in an infant. The methods include administering the infant formulas to an infant.

The present invention encompasses compositions and methods for treating or preventing malaria, compositions and methods for treating or preventing iron deficiency, and compositions and methods for simultaneously treating or preventing malaria and iron deficiency.

The present invention encompasses compositions and methods for treating or preventing malaria, compositions and methods for treating or preventing iron deficiency, and compositions and methods for simultaneously treating or preventing malaria and iron deficiency.

The present invention relates to a peptide with amidated carboxy terminus having melanogenesis inhibitory activity and a composition comprising same, and more specifically, to a peptide with amidated (—NH.sub.2) carboxy terminus, composed of one amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 9 to 18, and a pharmaceutical composition, cosmetic composition, and food composition for the treatment of pigmentation diseases comprising same as an active ingredient.

The present invention relates to a peptide with amidated carboxy terminus having melanogenesis inhibitory activity and a composition comprising same, and more specifically, to a peptide with amidated (—NH.sub.2) carboxy terminus, composed of one amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 9 to 18, and a pharmaceutical composition, cosmetic composition, and food composition for the treatment of pigmentation diseases comprising same as an active ingredient.